TIMP4

Summary

TIMP4 (TIMP metallopeptidase inhibitor 4, HGNC:11823) is a protein-coding gene on chromosome 3p25.2, encoding Metalloproteinase inhibitor 4 (Q99727). Complexes with metalloproteinases (such as collagenases) and irreversibly inactivates them by binding to their catalytic zinc cofactor.

This gene belongs to the TIMP gene family. The proteins encoded by this gene family are inhibitors of the matrix metalloproteinases, a group of peptidases involved in degradation of the extracellular matrix. The secreted, netrin domain-containing protein encoded by this gene is involved in regulation of platelet aggregation and recruitment and may play role in hormonal regulation and endometrial tissue remodeling.

Source: NCBI Gene 7079 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 1 total
• MANE Select transcript: NM_003256

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11823
Approved symbol	TIMP4
Name	TIMP metallopeptidase inhibitor 4
Location	3p25.2
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000157150
Ensembl biotype	protein_coding
OMIM	601915
Entrez	7079

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 2 protein_coding

ENST00000287814, ENST00000946698

RefSeq mRNA: 1 — MANE Select: NM_003256 NM_003256

CCDS: CCDS2608

Canonical transcript exons

ENST00000287814 — 5 exons

Exon	Start	End
ENSE00001030687	12154327	12154451
ENSE00001030688	12156820	12156934
ENSE00001030689	12157385	12157482
ENSE00001030692	12158702	12158912
ENSE00001030693	12153068	12153712

Expression profiles

Bgee: expression breadth ubiquitous, 224 present calls, max score 98.25.

FANTOM5 (CAGE): breadth broad, TPM avg 4.9424 / max 378.3238, expressed in 699 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
41113	4.3321	649
41112	0.2318	103
41117	0.1959	95
41115	0.0678	20
41118	0.0498	29
41114	0.0331	10
41116	0.0318	11

Top tissues by expression

286 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
adipose tissue of abdominal region	UBERON:0007808	98.25	gold quality
omental fat pad	UBERON:0010414	98.23	gold quality
peritoneum	UBERON:0002358	98.08	gold quality
adipose tissue	UBERON:0001013	97.57	gold quality
subcutaneous adipose tissue	UBERON:0002190	96.85	gold quality
connective tissue	UBERON:0002384	96.49	gold quality
thoracic aorta	UBERON:0001515	93.31	gold quality
left coronary artery	UBERON:0001626	93.23	gold quality
ascending aorta	UBERON:0001496	93.14	gold quality
apex of heart	UBERON:0002098	93.03	gold quality
synovial joint	UBERON:0002217	92.74	gold quality
right hemisphere of cerebellum	UBERON:0014890	92.64	gold quality
descending thoracic aorta	UBERON:0002345	92.51	gold quality
coronary artery	UBERON:0001621	92.37	gold quality
aorta	UBERON:0000947	91.80	gold quality
cerebellar cortex	UBERON:0002129	91.76	gold quality
cerebellar hemisphere	UBERON:0002245	91.75	gold quality
cerebellum	UBERON:0002037	91.28	gold quality
artery	UBERON:0001637	91.01	gold quality
popliteal artery	UBERON:0002250	90.89	gold quality
tibial artery	UBERON:0007610	90.85	gold quality
hindlimb stylopod muscle	UBERON:0004252	90.06	gold quality
heart left ventricle	UBERON:0002084	89.97	gold quality
cardiac ventricle	UBERON:0002082	89.49	gold quality
right lobe of thyroid gland	UBERON:0001119	89.24	gold quality
right atrium auricular region	UBERON:0006631	88.98	gold quality
layer of synovial tissue	UBERON:0007616	88.46	gold quality
cardiac atrium	UBERON:0002081	87.61	gold quality
heart	UBERON:0000948	87.47	gold quality
lower esophagus muscularis layer	UBERON:0035833	87.30	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): ESR1

miRNA regulators (miRDB)

25 targeting TIMP4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-96-5P	99.95	72.80	2140
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-12133	99.92	71.82	2006
HSA-MIR-1271-5P	99.91	71.99	1972
HSA-MIR-6783-3P	99.89	67.92	2059
HSA-MIR-1343-3P	99.89	66.78	1815
HSA-MIR-629-3P	99.85	67.99	1875
HSA-MIR-6752-3P	99.72	66.71	1587
HSA-MIR-10394-5P	99.65	66.83	1852
HSA-MIR-1205	99.65	66.76	1826
HSA-MIR-7106-5P	99.53	67.47	3574
HSA-MIR-7515	99.31	68.22	1795
HSA-MIR-6852-5P	99.17	66.69	2073
HSA-MIR-6868-5P	99.06	65.69	1284
HSA-MIR-3926	98.95	69.26	1438
HSA-MIR-4764-5P	98.88	65.53	894
HSA-MIR-3194-3P	98.83	66.22	1167
HSA-MIR-887-5P	98.82	65.90	1347
HSA-MIR-4635	98.74	67.63	1339
HSA-MIR-1237-3P	98.55	67.65	1423
HSA-MIR-6864-5P	98.38	66.59	1079
HSA-MIR-10226	98.25	66.50	811
HSA-MIR-1322	97.98	68.96	625
HSA-MIR-885-3P	95.14	63.08	448

Literature-anchored findings (GeneRIF, showing 40)

• TIMP-4 overexpression is associated with joint tissue remodeling and pathogenesis of osteoarthritic cartilage (PMID:11948685)
• investigation of structural and functional differences between TIMP-4 and TIMP-2 by mutagenesis into C-terminal tails (PMID:12374789)
• TIMP-4 is the major intraplatelet matrix metalloproteinase inhibitor and it is involved in regulation of platelet aggregation and recruitment. (PMID:12466243)
• Progress curve analysis of MMP inhibition by TIMP-4 indicates that association rate constants and inhibition constants are similar to those for other TIMPs; TIMP-4 has a 5-fold lower binding affinity for proMMP-2 than does TIMP-2. (PMID:12475252)
• Peaks during the early to mid-luteal phase. Seems to play role in hormonal regulation and endometrial tissue remodeling. (PMID:12969699)
• MMP-26 was colocalized with MMP-9, TIMP-2, and TIMP-4 in breast cancer cells. (PMID:14744773)
• Results suggest a functional relationship between TIMP-4 mRNA and MMP-26 mRNA, and possibly a role in human implantation. (PMID:15273280)
• TIMP-4 displayed negligible activity against TACE, N-TIMP-4 is a slow tight-binding inhibitor with low nanomolar binding affinity (PMID:15713681)
• TIMP-4 is expressed de novo in cervical cancer (PMID:15816637)
• In conclusion, the data demonstrate upregulation of TIMP4 in human cardiovascular disorders exhibiting inflammation, suggesting its future use as a novel systemic marker for vascular inflammation. (PMID:16521002)
• Maximal expression of TIMP-4 in the early and mid-secretory phase suggests its role during implantation and results show that TIMP-4 control the the relaese of MMP-26 in both stroma and uterine fluid. (PMID:16809379)
• Results indicate that MMP-26 and TIMP-4 may play an integral role during the conversion of high-grade prostatic intraepithelial neoplasia to invasive cancer and may also serve as markers for early prostate cancer diagnosis. (PMID:16940965)
• Enzyme immunoassays showed the levels of type 4 tissue inhibitor of metalloproteinases were virtually the same in colorectal cancer and mucosa. (PMID:18214300)
• C/T polymorphism which is located on the 3’-untranslational regions of the TIMP-4 gene might be associated with susceptibility to Osteoarthritis in a Korean population (PMID:18301898)
• Peroxynitrite-induced nitration and oligomerization of TIMP-4 attenuated its inhibitory activity against MMP-2 activity and endothelial or tumor cell invasiveness. (PMID:18336787)
• An imbalance between TIMP-1 and TIMP-4 serum levels is present in inflammatory bowel disease (ulcerative colitis and Crohn’s disease) patients. (PMID:19036126)
• TIMP4 is related to the development of KD with CALs in Korean children. (PMID:19048177)
• a cardiopulmonary vasculature-specific role of TIMP-4 activation in systemic sclerosis. (PMID:19190762)
• MMP-3 and TIMP-4 polymorphisms affect angiographic coronary plaque progression in type 2 diabetic and non-diabetic patients (PMID:19376102)
• TIMP-4 as a simple prognostic marker that may help identify patients with early-stage breast cancer who could benefit from more aggressive treatment at diagnosis (PMID:19700750)
• Expressions of MMP1, MMP9, TIMP4, and EMMPRIN were significantly unbalanced in the myocardium of congestive heart failure patients with rheumatic heart diseases. (PMID:19734590)
• MMP-10 and -7 abundance increased, accompanied by decreased TIMP-4 in dilated cardiomyopathy failing hearts compared with non-failing hearts. (PMID:20219015)
• this work provides the first evidence of a TIMP-4/CD63 association in astrocytoma tumor cells (PMID:20693981)
• TIMP4 expression is a downstream target of GCM1 (PMID:21406447)
• A trend toward increased serum levels of MMP-9/TIMP-4 was found in patients with successful arteriovenous fistulas. (PMID:21620625)
• Plasma TIMP-4 has a role in the prediction of LV remodeling and the pathophysiology of the heart postinfarction (PMID:21624734)
• Heterogeneous methylation in the promoter region of TIMP4 was associated with cancer progression in non-small cell lung cancer. (PMID:22018271)
• The rs3755724 in TIMP4 protein was nominally associated with schizophrenia with poor concentration. (PMID:23229788)
• Selective myocardial targeting for TIMP-4 induction through either a viral or transgenic approach favorably altered the course of adverse left ventricular remodeling post-myocardial infarction. (PMID:24637197)
• Data show that gene polymorphisms of TIMP metallopeptidase inhibitors TIMP-3 -1296 T>C (rs9619311) and TIMP-4 -55 T>C (rs3755724) were associated with the susceptibility of hepatocellular carcinoma among Taiwan women. (PMID:24903383)
• No evidence was found for any associations between the TIMP-1,-2,-3, or -4 gene single nucleotide polymorphisms with unexplained recurrent spontaneous abortions in this Han Chinese Han population. (PMID:25128867)
• Expression levels of TIMP-1, TIMP-3 and TIMP-4 were negligible (<10% of cells) in primary spontaneous pneumothorax lesions. (PMID:25300296)
• This study provides evidence that the promoter TIMP4 rs3755724 is a new focal epilepsy susceptibility variant that is plausibly involved in inflammation-induced seizures in Malaysian Chinese. (PMID:25595263)
• ncreased TGFB1 expression and decreased TIMP-4 expression correlated with atrial fibrosis and extracellular matrix changes in the atria of rheumatic heart disease patients with atrial fibrillation. (PMID:25971370)
• Upregulation of plasma TIMP-4 might contribute to PIH [pregnancy-induced hypertension] processes (PMID:25986893)
• regulates carcinogenesis through apoptosis activation in cervical cancer cells (PMID:26291714)
• TIMP1, TIMP2, and TIMP4 are increased in aqueous humor from primary open angle glaucoma patients. (PMID:26539028)
• This report provides the first example that TIMP-4 regulates carcinogenesis through enriching the tumor progenitor cell population in cervical cancer cells. (PMID:26618609)
• Our findings provide new evidence that LOX regulates SNAI2 expression and that SNAI2-mediated TIMP4 secretion plays a role in cancer progression. (PMID:27029493)
• Study evaluated MMP-12 and TIMP-1, TIMP-2, TIMP-3, and TIMP-4 levels in 40 patients with asymptomatic and symptomatic critical carotid artery stenosis (CAS) with neurologic symptoms onset within the preceding 12 hours; results suggest that MMP-12 is related to critical CAS independently on symptoms, moreover, TIMP-3 and TIMP-4 seem to be specifically related to stroke (PMID:27746079)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	timp4.3	ENSDARG00000100795
danio_rerio	timp4.2	ENSDARG00000102617
danio_rerio	timp4.1	ENSDARG00000111805
mus_musculus	Timp4	ENSMUSG00000030317
rattus_norvegicus	Timp4	ENSRNOG00000007955

Paralogs (3): TIMP2 (ENSG00000035862), TIMP3 (ENSG00000100234), TIMP1 (ENSG00000102265)

Protein

Protein identifiers

Metalloproteinase inhibitor 4 — Q99727 (reviewed: Q99727)

Alternative names: Tissue inhibitor of metalloproteinases 4

All UniProt accessions (1): Q99727

UniProt curated annotations — full annotation on UniProt →

Function. Complexes with metalloproteinases (such as collagenases) and irreversibly inactivates them by binding to their catalytic zinc cofactor. Known to act on MMP-1, MMP-2, MMP-3, MMP-7 and MMP-9.

Subcellular location. Secreted.

Tissue specificity. Abundant in heart and present at low levels in many other tissues.

Similarity. Belongs to the protease inhibitor I35 (TIMP) family.

RefSeq proteins (1): NP_003247* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001134	Netrin_domain	Domain
IPR001820	TIMP	Family
IPR008993	TIMP-like_OB-fold	Homologous_superfamily
IPR027465	TIMP_C	Homologous_superfamily
IPR030490	TIMP_CS	Conserved_site

Pfam: PF00965

UniProt features (13 total): disulfide bond 6, region of interest 2, signal peptide 1, chain 1, domain 1, binding site 1, site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q99727-F1	88.36	0.78

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 69 (involved in metalloproteinase-binding)

Ligand- & substrate-binding residues (1): 30

Disulfide bonds (6): 158–205, 163–168, 176–197, 30–102, 32–131, 42–156

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 147 (showing top): GOBP_NEGATIVE_REGULATION_OF_PROTEOLYSIS, MODULE_255, GOBP_RESPONSE_TO_PEPTIDE, GOCC_SECRETORY_GRANULE, CMYB_01, BHATI_G2M_ARREST_BY_2METHOXYESTRADIOL_DN, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, MODULE_317, SMID_BREAST_CANCER_RELAPSE_IN_LUNG_DN, CAGCTG_AP4_Q5, WOTTON_RUNX_TARGETS_UP, GOBP_NEGATIVE_REGULATION_OF_PROTEIN_CATABOLIC_PROCESS, CHEN_LVAD_SUPPORT_OF_FAILING_HEART_UP, GOBP_REGULATION_OF_CATABOLIC_PROCESS, GOBP_REGULATION_OF_MEMBRANE_PROTEIN_ECTODOMAIN_PROTEOLYSIS

GO Biological Process (4): Notch signaling pathway (GO:0007219), response to hormone (GO:0009725), response to cytokine (GO:0034097), negative regulation of membrane protein ectodomain proteolysis (GO:0051045)

GO Molecular Function (5): metalloendopeptidase inhibitor activity (GO:0008191), metal ion binding (GO:0046872), enzyme inhibitor activity (GO:0004857), protein binding (GO:0005515), peptidase inhibitor activity (GO:0030414)

GO Cellular Component (4): obsolete extracellular space (GO:0005615), extracellular matrix (GO:0031012), secretory granule lumen (GO:0034774), extracellular region (GO:0005576)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cell surface receptor signaling pathway	1
response to endogenous stimulus	1
response to chemical	1
response to peptide	1
membrane protein ectodomain proteolysis	1
negative regulation of protein catabolic process	1
negative regulation of proteolysis	1
regulation of membrane protein ectodomain proteolysis	1
metalloendopeptidase activity	1
endopeptidase inhibitor activity	1
cation binding	1
catalytic activity	1
enzyme regulator activity	1
molecular function inhibitor activity	1
binding	1
enzyme inhibitor activity	1
peptidase activity	1
peptidase regulator activity	1
external encapsulating structure	1
secretory granule	1
cytoplasmic vesicle lumen	1
cellular anatomical structure	1

Protein interactions and networks

STRING

988 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TIMP4	MMP2	P08253	918
TIMP4	MMP9	P14780	885
TIMP4	MMP14	P50281	869
TIMP4	MMP3	P08254	865
TIMP4	MMP8	P22894	813
TIMP4	HPX	P02790	797
TIMP4	MMP1	P03956	754
TIMP4	MMP26	Q9NRE1	715
TIMP4	SYN2	Q92777	699
TIMP4	TIMP2	P16035	697
TIMP4	EGFR	P00533	691
TIMP4	MMP7	P09237	677
TIMP4	S100A12	P80511	643
TIMP4	MMP12	P39900	641
TIMP4	TIMP3	P35625	629

IntAct

2 interactions, top by confidence:

A	B	Type	Score
TIMP4	COL14A1	psi-mi:“MI:0915”(physical association)	0.400

BioGRID (8): Pcsk5 (Affinity Capture-Western), TIMP4 (Two-hybrid), MMP2 (Reconstituted Complex), COL14A1 (Affinity Capture-MS), TIMP4 (Reconstituted Complex), TIMP4 (Affinity Capture-Luminescence), TIMP4 (Affinity Capture-Luminescence), CORO1C (Reconstituted Complex)

ESM2 similar proteins: A1A5X5, A1L2K1, A4D0V7, O02722, O42146, O54715, O97563, O97591, P01033, P01186, P10600, P12032, P15203, P16035, P16047, P17125, P20414, P20614, P24591, P25785, P30120, P30121, P35455, P35624, P40682, P49061, P50122, P55104, P81546, P81556, Q07258, Q13219, Q15904, Q5Q0T9, Q5RC60, Q5RJL6, Q641Q3, Q6Q484, Q7ZV46, Q8C1Q4

Diamond homologs: O02722, O42146, O73746, O77717, O97563, O97591, P01033, P12032, P16035, P16368, P20414, P20614, P25785, P26652, P30120, P30121, P35624, P35625, P39876, P48032, P49061, P50122, P61269, P79121, P81546, P81556, Q5PXZ9, Q5RC60, Q60453, Q95KL9, Q99727, Q9JHB3, Q9TRZ7, Q9TTY1, Q9TUL9, Q9W6B4, Q9WUC6, O97590, Q21265

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

1 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	1
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

692 predictions. Top by Δscore:

Variant	Effect	Δscore
3:12154319:T:A	donor_gain	1.0000
3:12154320:C:A	donor_gain	1.0000
3:12154321:CCTT:C	donor_loss	1.0000
3:12154322:CTTAC:C	donor_loss	1.0000
3:12154323:TTA:T	donor_loss	1.0000
3:12154324:T:TG	donor_loss	1.0000
3:12154325:A:AC	donor_gain	1.0000
3:12154325:A:AG	donor_loss	1.0000
3:12154326:C:CA	donor_loss	1.0000
3:12154326:C:CT	donor_gain	1.0000
3:12154326:CTTGG:C	donor_gain	1.0000
3:12154367:T:A	donor_gain	1.0000
3:12154447:CTGAC:C	acceptor_gain	1.0000
3:12154448:TGAC:T	acceptor_gain	1.0000
3:12154449:GAC:G	acceptor_gain	1.0000
3:12154452:C:CC	acceptor_gain	1.0000
3:12154452:C:CG	acceptor_loss	1.0000
3:12154455:C:CT	acceptor_gain	1.0000
3:12154464:A:C	acceptor_gain	1.0000
3:12156813:AACTT:A	donor_loss	1.0000
3:12156814:ACTT:A	donor_loss	1.0000
3:12156815:CTTA:C	donor_loss	1.0000
3:12156816:TTA:T	donor_loss	1.0000
3:12156817:TAC:T	donor_loss	1.0000
3:12156818:A:AC	donor_gain	1.0000
3:12156819:C:A	donor_loss	1.0000
3:12156819:C:CC	donor_gain	1.0000
3:12156932:CAT:C	acceptor_gain	1.0000
3:12156935:C:CC	acceptor_gain	1.0000
3:12156943:CAAT:C	acceptor_gain	1.0000

AlphaMissense

1467 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:12153656:C:A	W178C	0.999
3:12153656:C:G	W178C	0.999
3:12153663:C:G	C176S	0.998
3:12153664:A:T	C176S	0.998
3:12154393:C:A	W137C	0.998
3:12154393:C:G	W137C	0.998
3:12156867:C:G	C102S	0.998
3:12156868:A:T	C102S	0.998
3:12153569:C:A	W207C	0.997
3:12153569:C:G	W207C	0.997
3:12153600:C:G	C197S	0.997
3:12153601:A:T	C197S	0.997
3:12156825:A:G	L116S	0.997
3:12156828:A:G	L115P	0.997
3:12153664:A:G	C176R	0.996
3:12154412:C:G	C131S	0.996
3:12154413:A:T	C131S	0.996
3:12157473:G:T	A50D	0.996
3:12153599:A:C	C197W	0.995
3:12153600:C:T	C197Y	0.995
3:12153601:A:G	C197R	0.995
3:12153701:G:C	C163W	0.995
3:12154331:C:G	C158S	0.995
3:12154332:A:T	C158S	0.995
3:12156930:A:C	F81C	0.995
3:12157474:C:G	A50P	0.995
3:12157476:C:G	R49P	0.995
3:12153658:A:G	W178R	0.994
3:12153658:A:T	W178R	0.994
3:12153662:G:C	C176W	0.994

dbSNP variants (sampled 300 via entrez): RS1000388727 (3:12158340 T>C,G), RS1000457963 (3:12152763 A>C), RS1000751587 (3:12158557 C>G), RS1001365306 (3:12157314 C>T), RS1001795055 (3:12156961 A>G), RS1002275944 (3:12155524 C>G,T), RS1002358273 (3:12155834 A>C), RS1002383983 (3:12155984 T>C), RS1002389471 (3:12155666 G>A), RS1002940566 (3:12158915 C>T), RS1003192981 (3:12159681 T>C), RS1003282203 (3:12156739 G>A,C), RS1003381145 (3:12154134 G>C,T), RS1003906524 (3:12159889 A>G), RS1004601194 (3:12154237 T>C)

Disease associations

OMIM: gene MIM:601915 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST005956_72	Waist-to-hip ratio adjusted for BMI	1.000000e-07
GCST005957_11	Waist-to-hip ratio adjusted for BMI (age <50)	9.000000e-06
GCST005958_19	Waist-to-hip ratio adjusted for BMI (age >50)	2.000000e-06
GCST005962_29	Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test)	9.000000e-09
GCST006585_2539	Blood protein levels	2.000000e-33
GCST010244_399	Triglyceride levels	2.000000e-10

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0007788	BMI-adjusted waist-hip ratio
EFO:0008007	age at assessment
EFO:0008343	sex interaction measurement
EFO:0004530	triglyceride measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

50 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Cisplatin	affects cotreatment, increases expression, affects expression	3
entinostat	increases expression, affects cotreatment	2
Benzo(a)pyrene	decreases methylation, increases expression, increases methylation	2
Dexamethasone	increases expression, affects cotreatment	2
Nickel	decreases expression	2
Tobacco Smoke Pollution	decreases expression	2
Valproic Acid	affects expression, increases expression	2
bisphenol A	increases expression	1
potassium perchlorate	decreases expression	1
terbufos	increases methylation	1
sulforaphane	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
sodium arsenite	increases expression	1
coumarin	increases expression	1
triadimefon	decreases expression	1
benazol P	affects expression	1
S-(1,2-dichlorovinyl)cysteine	increases expression, affects cotreatment, affects response to substance	1
CGP 52608	affects binding, increases reaction	1
3-nitrobenzanthrone	affects expression	1
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine	increases expression	1
monomethylarsonous acid	increases expression	1
scriptaid	affects expression	1
lipopolysaccharide, E. coli O26-B6	affects expression, affects cotreatment	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	increases expression, affects cotreatment	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
MRK 003	decreases expression	1
jinfukang	affects cotreatment, increases expression	1
NSC 689534	affects binding, increases expression	1
Resveratrol	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.